Press Releases Silence Therapeutics plc OTC Markets

Equities

SLNCF

GB00B9GTXM62

Delayed OTC Markets Other stock markets 16:26:37 08/05/2024 BST			5-day change	1st Jan Change
7 ^USD	-12.50%		-12.50%	+366.67%

05-09	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
04-29	Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference	04-30	BU
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors	04-29	BU
Silence Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION - Form 6-K	04-15	PU
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)	04-08	BU
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	03-13	BU
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)	03-13	BU
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024	02-28	BU
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial	02-26	AQ
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial	02-23	BU
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement	02-05	BU
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01-31	BU
Gubra concludes the research agreement with UK Biotech	01-26	AQ
Silence Therapeutics : Curtis Rambaran, MD, promoted to Chief Medical Officer Marie Wikström Lindholm, PhD, promoted to Chief Scientific Officer - Form 6-K	12-01	PU
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments	12-01	BU
Moa Technology hires for further growth with expansion of its leadership team – announcing appointment of CFO and US-based CBO to support advancement of next-generation herbicides	11-20	AQ
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results	11-14	BU
Silence Therapeutics to Present at Jefferies London Healthcare Conference	11-08	BU
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease	11-01	BU
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference	26/09/23	BU
Silence Therapeutics to Participate in September Investor Conferences	06/09/23	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Silence Therapeutics plc OTC Markets

Equities

SLNCF

GB00B9GTXM62

Press Releases

Filters